Cargando…

Potential therapeutic impact of CD13 expression in non-small cell lung cancer

BACKGROUND: Aminopeptidase N (CD13) is a zinc-binding protease that has functional effects on both cancerogenesis and tumor angiogenesis. Since CD13 is an antigen suitable for molecular targeted therapies (e.g. tTF-NGR induced tumor vascular infarction), we evaluated its impact in NSCLC patients, an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schmidt, Lars Henning, Brand, Caroline, Stucke-Ring, Janine, Schliemann, Christoph, Kessler, Torsten, Harrach, Saliha, Mohr, Michael, Görlich, Dennis, Marra, Alessandro, Hillejan, Ludger, Müller-Tidow, Carsten, Lenz, Georg, Wardelmann, Eva, Wiewrodt, Rainer, Berdel, Wolfgang E., Schwöppe, Christian, Hartmann, Wolfgang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5467809/ https://www.ncbi.nlm.nih.gov/pubmed/28604784 http://dx.doi.org/10.1371/journal.pone.0177146

Ejemplares similares

Correction: Potential therapeutic impact of CD13 expression in non-small cell lung cancer
por: Schmidt, Lars Henning, et al.
Publicado: (2017)

Combinatorial effects of doxorubicin and retargeted tissue factor by intratumoral entrapment of doxorubicin and proapoptotic increase of tumor vascular infarction
por: Stucke-Ring, Janine, et al.
Publicado: (2016)

Prostate specific membrane antigen (PSMA) expression in non-small cell lung cancer
por: Schmidt, Lars Henning, et al.
Publicado: (2017)

Multiparametric Magnetic Resonance Imaging for Immediate Target Hit Assessment of CD13—Targeted Tissue Factor tTF-NGR in Advanced Malignant Disease
por: Gerwing, Mirjam, et al.
Publicado: (2021)

PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups
por: Schmidt, Lars Henning, et al.
Publicado: (2015)

Animal Safety, Toxicology, and Pharmacokinetic Studies According to the ICH S9 Guideline for a Novel Fusion Protein tTF-NGR Targeting Procoagulatory Activity into Tumor Vasculature: Are Results Predictive for Humans?
por: Berdel, Wolfgang E., et al.
Publicado: (2020)

Aminopeptidase N (CD13): Expression, Prognostic Impact, and Use as Therapeutic Target for Tissue Factor Induced Tumor Vascular Infarction in Soft Tissue Sarcoma
por: Kessler, Torsten, et al.
Publicado: (2018)

Targeting Tissue Factor to Tumor Vasculature to Induce Tumor Infarction
por: Berdel, Andrew F., et al.
Publicado: (2021)

Radiation synergizes with antitumor activity of CD13-targeted tissue factor in a HT1080 xenograft model of human soft tissue sarcoma
por: Brand, Caroline, et al.
Publicado: (2020)

NG2 proteoglycan as a pericyte target for anticancer therapy by tumor vessel infarction with retargeted tissue factor
por: Brand, Caroline, et al.
Publicado: (2016)

Mutations of the EPHB6 Receptor Tyrosine Kinase Induce a Pro-Metastatic Phenotype in Non-Small Cell Lung Cancer
por: Bulk, Etmar, et al.
Publicado: (2012)

CAR T cells as micropharmacies against solid cancers: Combining effector T-cell mediated cell death with vascular targeting in a one-step engineering process
por: Altvater, Bianca, et al.
Publicado: (2023)

Prognostic factors of resected node-positive lung cancer: location, extent of nodal metastases, and multimodal treatment
por: Marra, Alessandro, et al.
Publicado: (2011)

Thoracic Malignancies and Pulmonary Nodules in Patients under Evaluation for Transcatheter Aortic Valve Implantation (TAVI): Incidence, Follow Up and Possible Impact on Treatment Decision
por: Schmidt, Lars Henning, et al.
Publicado: (2016)

First-In-Class CD13-Targeted Tissue Factor tTF-NGR in Patients with Recurrent or Refractory Malignant Tumors: Results of a Phase I Dose-Escalation Study
por: Schliemann, Christoph, et al.
Publicado: (2020)

High Expression of NT5DC2 Is a Negative Prognostic Marker in Pulmonary Adenocarcinoma
por: Schulze, Arik Bernard, et al.
Publicado: (2022)

Rapid response to systemic bevacizumab therapy in recurrent respiratory papillomatosis
por: MOHR, MICHAEL, et al.
Publicado: (2014)

Tumor infiltrating T cells influence prognosis in stage I–III non-small cell lung cancer
por: Schulze, Arik Bernard, et al.
Publicado: (2020)

Downregulation of PIK3CA via antibody-esiRNA-complexes suppresses human xenograft tumor growth
por: Bäumer, Nicole, et al.
Publicado: (2018)

Adjuvant chemotherapy—Radiotherapy—Chemotherapy sandwich protocol in resectable soft tissue sarcoma: An updated single-center analysis of 104 cases
por: Schliemann, Christoph, et al.
Publicado: (2018)

Integrated RNAi screening identifies the NEDDylation pathway as a synergistic partner of azacytidine in acute myeloid leukemia
por: Klosner, Justine, et al.
Publicado: (2021)

NOP10 predicts lung cancer prognosis and its associated small nucleolar RNAs drive proliferation and migration
por: Cui, Chunhong, et al.
Publicado: (2020)

Analysis of a novel highly metastatic melanoma cell line identifies osteopontin as a new lymphangiogenic factor
por: LIERSCH, RUEDIGER, et al.
Publicado: (2012)

Prognostic impact of CD34 and SMA in cancer‐associated fibroblasts in stage I–III NSCLC
por: Schulze, Arik Bernard, et al.
Publicado: (2019)

Amsacrine-based induction therapy in AML patients with cardiac comorbidities: a retrospective single-center analysis
por: Kuron, David, et al.
Publicado: (2023)

Perioperative Chemotherapy in Gastroesophageal Cancer. A Retrospective Monocenter Evaluation of 42 Cases
por: Brehler, Ann-Christin E., et al.
Publicado: (2015)

Future Options of Molecular-Targeted Therapy in Small Cell Lung Cancer
por: Schulze, Arik Bernard, et al.
Publicado: (2019)

Workflow to improve patient recruitment for clinical trials within hospital information systems – a case-study
por: Dugas, Martin, et al.
Publicado: (2008)

Electrostatic anti-CD33-antibody–protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia
por: Bäumer, Nicole, et al.
Publicado: (2022)

The role of autologous stem cell transplantation (ASCT) in aggressive B-cell lymphomas: real-world data from a retrospective single-center analysis
por: Wullenkord, Ramona, et al.
Publicado: (2021)

Long-term survival and polyclonal immunoglobulin reconstitution after allogeneic stem cell transplantation in multiple myeloma
por: Eisfeld, Christine, et al.
Publicado: (2020)

Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapse
por: Berdel, Andrew F., et al.
Publicado: (2022)

Magnesium levels and outcome after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia
por: Angenendt, Linus, et al.
Publicado: (2020)

Gadofosveset-enhanced MRI as simple surrogate parameter for real-time evaluation of the initial tumour vessel infarction by retargeted tissue factor tTF-NGR
por: Höink, Anna, et al.
Publicado: (2019)

The Inhibitor of Growth Protein 5 (ING5) Depends on INCA1 as a Co-Factor for Its Antiproliferative Effects
por: Zhang, Feng, et al.
Publicado: (2011)

A Limited Role for the Cell Cycle Regulator Cyclin A1 in Murine Leukemogenesis
por: Bäumer, Nicole, et al.
Publicado: (2015)

Correction: Patients with Acute Myeloid Leukemia Admitted to Intensive Care Units: Outcome Analysis and Risk Prediction
por: Pohlen, Michele, et al.
Publicado: (2018)

Metastatic triple-negative breast cancer patient with TP53 tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse events
por: Meißner, Tobias, et al.
Publicado: (2017)

Patients with Acute Myeloid Leukemia Admitted to Intensive Care Units: Outcome Analysis and Risk Prediction
por: Pohlen, Michele, et al.
Publicado: (2016)

Maintenance of Leukemia-Initiating Cells Is Regulated by the CDK Inhibitor Inca1
por: Bäumer, Nicole, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_d4ds7v8sf53ape8406qpjguigk